Back to Search
ALYSSA HEISER, MD
MD
Otolaryngology Physician
NPI: 1669177556Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
3014220(MA)
Otolaryngology PhysicianPrimary
Otolaryngology
Code: 207Y00000X
3014220(MA)
Research & Publications (19)
Parental and professional agreement in developmental assessment of very-low-birthweight and term infants.
PMID 10665971·Dev Med Child Neurol·2000
8-other
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
PMID 19088044·Clin Cancer Res·2008
8-other
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
PMID 18566400·J Immunol·2008
7-preclinical
LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer.
PMID 18499440·Eur J Cancer·2008
8-other
Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer.
PMID 18202753·Int J Oncol·2008
8-other
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
PMID 16495249·Antimicrob Agents Chemother·2006
4-observational
The impact of electrical charge on the viability and physiology of dendritic cells.
PMID 16253128·Scand J Immunol·2005
8-other
Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
PMID 15729371·Gene Ther·2005
7-preclinical
A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
PMID 15121224·Auris Nasus Larynx·2004
8-other
Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
PMID 12759413·J Immunol·2003
7-preclinical
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
PMID 12727829·Cancer Res·2003
3-trial
Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.
PMID 12183689·J Pharmacol Exp Ther·2002
7-preclinical
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
PMID 11828001·J Clin Invest·2002
8-other
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.
PMID 11447770·Drugs Exp Clin Res·2001
7-preclinical
Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.
PMID 11309297·Cancer Res·2001
8-other
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
PMID 11207244·J Immunol·2001
8-other
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
PMID 10973321·Nat Med·2000
7-preclinical
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
PMID 10799919·J Immunol·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 800 WASHINGTON ST
BOSTON, MA 02111 - Phone
- (617) 636-5000
Quick Facts
- NPI
- 1669177556
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 19
Are you this provider?
Claim Your Profile